menu search

IFRX / InflaRx (IFRX) Stock Pops as FDA Grants Emergency Use Authorization

InflaRx (IFRX) Stock Pops as FDA Grants Emergency Use Authorization
InflaRx (NASDAQ: IFRX ) stock is getting a boost on Wednesday following an update from the FDA concerning its Covid-19 treatment. The big news investors are celebrating today is vilobelimab getting Emergency Use Authorization (EUA) from the FDA. Read More
Posted: Apr 5 2023, 10:06
Author Name: InvestorPlace
Views: 103182

IFRX News  

InflaRx: Small German Company Targeting A Rare Indication

By Seeking Alpha
September 6, 2023

InflaRx: Small German Company Targeting A Rare Indication

InflaRx is a developer of complement mediated therapies for inflammatory diseases. Their lead asset, vilobelimab, is a C5a inhibitor targeting Pyoderm more_horizontal

InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why

By Zacks Investment Research
September 1, 2023

InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why

Shares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatme more_horizontal

Why InflaRx Stock Skyrocketed This Week

By The Motley Fool
April 7, 2023

Why InflaRx Stock Skyrocketed This Week

InflaRx stock has soared on news that the company's Gohibic drug had received Emergency Use Authorization from the FDA. Analysts expect that Gohibic w more_horizontal

InflaRx shares pop on FDA emergency use authorization of Covid-19 treatment injection

By Proactive Investors
April 5, 2023

InflaRx shares pop on FDA emergency use authorization of Covid-19 treatment injection

The US Food and Drug Administration (FDA) granted emergency-use authorization (EUA) to InflaRx NV's monoclonal antibody for the treatment of hospital more_horizontal

InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment

By Zacks Investment Research
April 5, 2023

InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment

InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patie more_horizontal

Why Shares of InflaRx Are Soaring Wednesday

By The Motley Fool
April 5, 2023

Why Shares of InflaRx Are Soaring Wednesday

InflaRx is a clinical-stage biotech that focuses on anti-inflammation therapies. Its lead therapy is also seen as a treatment for several skin disorde more_horizontal

InflaRx (IFRX) Stock Pops as FDA Grants Emergency Use Authorization

By InvestorPlace
April 5, 2023

InflaRx (IFRX) Stock Pops as FDA Grants Emergency Use Authorization

InflaRx (NASDAQ: IFRX ) stock is getting a boost on Wednesday following an update from the FDA concerning its Covid-19 treatment. The big news investo more_horizontal

InflaRx: On Watch For A Buy During Tax Loss Selling Season

By Seeking Alpha
December 14, 2022

InflaRx: On Watch For A Buy During Tax Loss Selling Season

IFRX has been beaten down much like many other biotech companies. The company has a lead drug which is being considered for EUA in the US and use in t more_horizontal


Search within

Pages Search Results: